scPharmaceuticals News

Craig-Hallum Remains a Buy on ScPharmaceuticals (SCPH)

TipRanksApr 25 09:15 ET

Express News | ScPharmaceuticals Inc - Anticipates Topline Data in Q3 2024, Followed by a Supplemental New Drug Application (Snda) by Year-End 2024, IF Successful

Moomoo 24/7Apr 24 08:02 ET

Express News | ScPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection

Moomoo 24/7Apr 24 08:02 ET

Express News | ScPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection

Moomoo 24/7Apr 24 08:01 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N

BenzingaApr 5 08:09 ET

Buy Rating Affirmed for ScPharmaceuticals Amidst Revenue Surge and Solid Financial Footing

TipRanksMar 15 07:25 ET

Express News | HC Wainwright & Co. Reiterates Buy on ScPharmaceuticals, Maintains $18 Price Target

Moomoo 24/7Mar 14 07:23 ET

ScPharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 229.07% HC Wainwright & Co. → $18 Reiterates Buy → Buy 09/07/2023 265.63% Craig-Hallum → $20 In

BenzingaMar 14 07:22 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and ScPharmaceuticals (SCPH)

TipRanksMar 14 06:20 ET

Strong Buy Recommendation for ScPharmaceuticals on Furoscix's Successful Launch and Growth Prospects

TipRanksMar 13 20:15 ET

ScPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth

Yahoo FinanceMar 13 17:33 ET

ScPharmaceuticals Files for $200M Mixed Shelf Offering

Seeking AlphaMar 13 17:05 ET

Recap: ScPharmaceuticals Q4 Earnings

scPharmaceuticals (NASDAQ:SCPH) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsscPharmaceuticals beat estim

BenzingaMar 13 16:10 ET

ScPharmaceuticals GAAP EPS of -$0.35 Beats by $0.07, Revenue of $6.1M Beats by $0.33M

Seeking AlphaMar 13 16:06 ET

ScPharmaceuticals 4Q Loss $13.8M >SCPH

ScPharmaceuticals 4Q Loss $13.8M >SCPH

Dow JonesMar 13 16:01 ET

Press Release: ScPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update.

Dow JonesMar 13 16:01 ET

Earnings Scheduled For March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec

BenzingaMar 13 06:15 ET

Notable Earnings After Wednesday's Close

Seeking AlphaMar 12 17:35 ET

ScPharmaceuticals Q4 2023 Earnings Preview

Seeking AlphaMar 12 17:35 ET

A Preview Of ScPharmaceuticals's Earnings

scPharmaceuticals (NASDAQ:SCPH) is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Here's what investors need to know before the announcement.Analysts estimate that scPharma

BenzingaMar 12 11:01 ET